New Subvariant COVID Vaccine May Be Coming

May 28, 2026 – Federal health advisers are weighing a crucial update to the upcoming 2026–2027 COVID-19 vaccine formula to counter a stealthy new variant that has taken over as the dominant strain across the country.

According to internal Food and Drug Administration (FDA) advisory panel documents, the agency’s independent experts are evaluating a pivot to target the XFG subvariant, scientifically cataloged as NB.1.8.1 and colloquially known as the “Stratus” variant. The advisory panel is scheduled to vote on the updated vaccine formula later this week.

A Model Mirroring the Seasonal Flu

This planned formula adjustment signals a broader, permanent shift in how public health infrastructure manages COVID-19. Rather than relying on sporadic booster campaigns triggered by unexpected surges, officials are transitioning toward a predictable, annualized schedule—a model heavily mirrored by the seasonal flu shot.

Every year, scientists track mutating strains of the influenza virus across the globe to predict which variants will be most active during the winter months. The FDA and manufacturers then update the annual flu vaccine in the spring to match those predictions, allowing updated shots to be distributed every fall.

The current evaluation of the XFG strain represents the same routine optimization for COVID-19. Because coronavirus strains continue to experience rapid genetic drift, health officials are moving toward a standard routine where Americans can expect a single, combined, or concurrent yearly vaccination appointment every autumn to handle both influenza and the dominant COVID variant of the year.

The Dominant ‘Stratus’ Strain

Data from the U.S. Centers for Disease Control and Prevention (CDC) previously confirmed that the XFG subvariant surged to account for a clear majority of COVID-19 cases in the United States over a four-week window ending April 11. This dominant footprint follows a broader trend from last fall, when the CDC reported rising coronavirus cases across nine states.

Medical researchers note that while XFG spreads efficiently, its biological traits differ from past disruptive variants:

• High Evasion, Lower Infection Strength: Analysis from Stony Brook Medicine in New York indicates that the XFG strain is less efficient at physically entering human cells than its predecessors. However, it is significantly better at dodging existing immune defenses.
• Mild Severity: Because of this unique combination, the variant spreads easily by flying under the immune system’s radar, but it is not inherently more infectious once exposed to cells, nor is it linked to an increase in severe symptoms.

Leadership Transition at the FDA

The high-stakes decision on the next vaccine formulation arrives during a period of abrupt administrative turnover at the nation’s top food and drug regulator.

Earlier this month, FDA Commissioner Dr. Marty Makary resigned from his post. Following his departure, Kyle Diamantas—who was serving as the agency’s chief for human foods—stepped in as the acting FDA commissioner.

Diamantas, an attorney by trade, marks a shift in traditional leadership backgrounds for the agency. Reporting highlights that the new acting chief maintains close personal ties to Donald Trump Jr.

Despite the sudden shakeup at the helm of the FDA, the scheduled panel vote will proceed as manufacturers prepare the logistics for the fall inoculation campaign.